Boston Scientific Corporation
BSX Healthcare Medical - Devices NYSE
$71.80
$-1.19 (-1.63%)
Open: $72.90 | High: $72.94 | Low: $71.08 | Prev Close: $72.99
Market Cap: $106.54B
Volume: 5.3M | Avg: 14.5M
Last updated: March 06, 2026 at 08:00 PMInvestment Rating
Neutral
Overall Score: 60/100
Rating Breakdown:
Stock Score Analysis
Stock Score: 602
Comprehensive Quality Assessment
Component Breakdown:
Valuation Metrics
| P/E Ratio | 37.01 |
| P/B Ratio | 4.39 |
| P/S Ratio | 5.31 |
| EPS | $1.94 |
| Beta | 0.70 |
| Shares Outstanding | 1.48B |
| 52-Week High | $109.50 |
| 52-Week Low | $70.75 |
| SMA 50 | $86.14 |
| SMA 200 | $97.66 |
| Next Earnings | April 22, 2026 01:30 PM ET |
Financial Ratios
| Gross Margin | 69.0% |
| Operating Margin | 19.8% |
| Net Margin | 14.4% |
| ROE | 12.5% |
| ROA | 6.6% |
| Debt/Equity | 0.51 |
| Current Ratio | 1.62 |
| Quick Ratio | 1.08 |
Balance Sheet
| Total Assets | $43.67B |
| Total Liabilities | $19.20B |
| Total Equity | $24.23B |
|
|
|
| Cash | $2.04B |
| Total Debt | $12.42B |
| Net Debt | $10.37B |
Income Statement
| Revenue | $20.07B |
| Gross Profit | $13.85B |
| Operating Income | $3.97B |
| Net Income | $2.89B |
|
|
|
| EBITDA | $3.73B |
| Revenue/Share | $13.54 |
Cash Flow
| Operating CF | $4.53B |
| CapEx | $876.00M |
| Free Cash Flow | $3.66B |
|
|
|
| Book Value/Share | $16.51 |
| Tangible Book/Share | $-0.56 |
| Equity/Share | $16.34 |
Technical Indicators
| RSI (14) | 33.51 Neutral |
| MACD |
-3.65
Signal: -3.91
|
| Volatility | 46.37% |
| Trading Signal | Bullish |
Performance & Returns
| 1 Year | -32.68% |
| Sharpe Ratio | -1.96 Poor |
| Volatility (Ann.) | 26.28% Moderate |
| BSX (1Y) | -32.68% |
| S&P 500 (1Y) | +13.03% |
| Alpha (Excess Return) | -45.72% |
Sector Comparison (Healthcare)
| Metric | BSX | Sector Avg | Percentile |
|---|---|---|---|
| P/E Ratio | 37.01 | 27.48 | 76% |
| P/B Ratio | 4.39 | -19.61 | 62% |
| ROE (%) | 12.53% | -9.53% | 47% |
| Net Margin (%) | 14.40% | 9.22% | 59% |
| Stock Score | 602 | 542.0 | 72% |
| 1Y Return (%) | -32.68 % | +8.94 % | 6% |
📊 Historical Price Analysis (Last 200 Days)
Loading chart...
Technical Analysis
| Ticker | Close | SMA 5 | SMA 8 | SMA 13 | SMA 50 | SMA 200 | RSI (14) | MACD | Volatility (%) | Volume | Signal | SMA Decision |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| BSX | $71.80 | $73.07 | $73.91 | $74.45 | $85.68 | $97.49 | 33.51 | -3.65 | 46.37% | 3709244 | Strong Short | Bearish Stack |
Candlestick Patterns
There wasn't any recognizable pattern for the BSX stock
News Sentiment
| 📊 Ticker | 📰 Headline | 💭 Sentiment | 📡 Source | 🔗 URL |
|---|---|---|---|---|
| BSX | BSX Shareholder Alert: Investors With Losses May Seek to Lead the Class Action in Boston Scientific Corporation Securities Lawsuit — The Gross Law Firm | Negative | globenewswire.com | Read More |
| BSX | ROSEN, SKILLED INVESTOR COUNSEL, Encourages Boston Scientific Corporation Investors to Secure Counsel Before Important Deadline in Securities Class Action - BSX | Neutral | newsfilecorp.com | Read More |
| BSX | INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Boston Scientific Corporation of Class Action Lawsuit and Upcoming Deadlines - BSX | Negative | prnewswire.com | Read More |
| BSX | Why Boston Scientific (BSX) Dipped More Than Broader Market Today | Neutral | zacks.com | Read More |
| BSX | Deadline Alert: Boston Scientific Corporation (BSX) Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP About Securities Fraud Lawsuit | Neutral | businesswire.com | Read More |
Recent Insider Trading
No recent insider trading data available for BSX
Company Information
Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through three segments: MedSurg, Rhythm and Neuro, and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions; devices to treat various urological and pelvic conditions; implantable cardioverter and implantable cardiac resynchronization therapy defibrillators; pacemakers and implantable cardiac resynchronization therapy pacemakers; and remote patient management systems. It also provides medical technologies to diagnose and treat rate and rhythm disorders of the heart comprising 3-D cardiac mapping and navigation solutions, ablation catheters, diagnostic catheters, mapping catheters, intracardiac ultrasound catheters, delivery sheaths, and other accessories; spinal cord stimulator systems for the management of chronic pain; indirect decompression systems; and deep brain stimulation systems. In addition, the company offers interventional cardiology products, including drug-eluting coronary stent systems used in the treatment of coronary artery disease; percutaneous coronary interventions products to treat atherosclerosis; intravascular catheter-directed ultrasound imaging catheters, fractional flow reserve devices, and systems for use in coronary arteries and heart chambers, as well as various peripheral vessels; and structural heart therapies. Further, it provides stents, balloon catheters, wires, and atherectomy systems to treat arterial diseases; thrombectomy and acoustic pulse thrombolysis systems, wires, and stents to treat venous diseases; and peripheral embolization devices, radioactive microspheres, ablation systems, cryotherapy ablation systems, and micro and drainage catheters to treat cancer. The company was incorporated in 1979 and is headquartered in Marlborough, Massachusetts.
| CEO | Michael F. Mahoney |
| Employees | 53000 |
| Country | US |
| IPO Date | 1992-05-19 |
| Exchange | NYSE |
| Website | https://www.bostonscientific.com |
| Sector | Healthcare |
| Industry | Medical - Devices |
Similar Stocks (Healthcare - Medical - Devices)
Rating Metrics Explained
DCF Score (Discounted Cash Flow)
Measures the intrinsic value of the stock based on projected future cash flows. A higher score indicates the stock is undervalued relative to its DCF valuation.
ROE Score (Return on Equity)
Evaluates how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better profitability and management effectiveness.
ROA Score (Return on Assets)
Measures how efficiently a company uses its assets to generate profit. A higher ROA means better asset utilization and operational efficiency.
D/E Score (Debt-to-Equity)
Assesses the company's financial leverage and risk. Lower debt-to-equity ratios indicate less financial risk and better balance sheet health.
P/E Score (Price-to-Earnings)
Compares stock price to earnings per share. A lower P/E ratio may indicate the stock is undervalued, while a higher ratio could suggest overvaluation or growth expectations.
P/B Score (Price-to-Book)
Compares market price to book value per share. Lower P/B ratios may indicate undervaluation relative to the company's net asset value.
Rating Recommendations:
Each metric is scored on a scale of 1-5, where the scores are determined by comparing the company's performance against industry benchmarks and historical data:
-
Strong Buy (5/5): Excellent score - strong positive indicator
- The metric significantly outperforms industry averages (top 20% of companies)
- Indicates exceptional financial health or attractive valuation in that category
-
Buy (4/5): Good score - positive indicator
- Above-average performance (top 40% of companies)
- Shows strong fundamentals with room for improvement
-
Neutral (3/5): Average score - neutral indicator
- Performance in line with industry median (middle 20%)
- Neither significantly positive nor negative signal
-
Sell (2/5): Below average - negative indicator
- Below-average performance (bottom 40% of companies)
- Suggests weakness in this particular metric
-
Strong Sell (1/5): Poor score - strong negative indicator
- Significantly underperforms industry (bottom 20%)
- Indicates potential risk or overvaluation in that category